158 related articles for article (PubMed ID: 521836)
1. Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease.
Quik M; Spokes EG; Mackay AV; Bannister R
J Neurol Sci; 1979 Nov; 43(3):429-37. PubMed ID: 521836
[TBL] [Abstract][Full Text] [Related]
2. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.
Bokobza B; Ruberg M; Scatton B; Javoy-Agid F; Agid Y
Eur J Pharmacol; 1984 Mar; 99(2-3):167-75. PubMed ID: 6734727
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the binding of [3H]spiperone and [3H]domperidone in homogenates of mammalian retina and caudate nucleus.
Watling KJ; Iversen LL
J Neurochem; 1981 Nov; 37(5):1130-43. PubMed ID: 7299392
[TBL] [Abstract][Full Text] [Related]
4. [3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease.
Nishino N; Noguchi-Kuno SA; Sugiyama T; Tanaka C
Brain Res; 1986 Jul; 377(1):186-9. PubMed ID: 2942224
[TBL] [Abstract][Full Text] [Related]
5. Resolution of dopamine and serotonin receptor components of [3H]spiperone binding to rat brain regions.
List SJ; Seeman P
Proc Natl Acad Sci U S A; 1981 Apr; 78(4):2620-4. PubMed ID: 6941314
[TBL] [Abstract][Full Text] [Related]
6. [3H]spiperone binding in the nigrostriatal system in human brain.
Ruberg M; Bokobza B; Javoy-Agid F; Montfort JC; Agid Y
Eur J Pharmacol; 1984 Mar; 99(2-3):159-65. PubMed ID: 6203765
[TBL] [Abstract][Full Text] [Related]
7. Dissociation between the presynaptic dopamine-sensitive adenylate cyclase and [3H]spiperone binding sites in rat substantia nigra.
Quik M; Emson PC; Joyce E
Brain Res; 1979 May; 167(2):355-65. PubMed ID: 36204
[TBL] [Abstract][Full Text] [Related]
8. Prenatal reserpine exposure in rats decreases caudate nucleus dopamine receptor binding in female offspring.
Ali SF; Buelke-Sam J; Slikker W
Toxicol Lett; 1986 Jun; 31(3):195-201. PubMed ID: 3726897
[TBL] [Abstract][Full Text] [Related]
9. Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists.
Lehmann J; Briley M; Langer SZ
Eur J Pharmacol; 1983 Mar; 88(1):11-26. PubMed ID: 6133762
[TBL] [Abstract][Full Text] [Related]
10. Irreversible blockade of [3H]spiperone- but not [3H]dopamine-labeled dopamine receptors with phenoxybenzamine.
Titeler M
Biochem Pharmacol; 1981 Nov; 30(22):3031-7. PubMed ID: 7337719
[No Abstract] [Full Text] [Related]
11. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
Bennett JP; Wooten GF
Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
[TBL] [Abstract][Full Text] [Related]
12. 3H-Spiroperidol binding and dopamine-stimulated adenylate cyclase: evidence for multiple classes of receptors in primate brain regions.
Thal LJ; Makman MH; Ahn HS; Mishra RK; Horowitz SG; Dvorkin B; Katzman R
Life Sci; 1978 Aug; 23(6):629-33. PubMed ID: 99609
[No Abstract] [Full Text] [Related]
13. Differential anatomical location of [3H]-N,n-propylnorapomorphine and [3H]-spiperone binding sites in the striatum and substantia nigra of the rat.
Hall MD; Jenner P; Kelly E; Marsden CD
Br J Pharmacol; 1983 Jun; 79(2):599-610. PubMed ID: 6418246
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease as a model for changes in dopamine receptor dynamics with aging.
Rinne UK
Gerontology; 1982; 28 Suppl 1():35-52. PubMed ID: 7044903
[TBL] [Abstract][Full Text] [Related]
15. Autoradiographic localization of neuroleptic and dopamine receptors in the caudate-putamen and substantia nigra: effects of lesions.
Murrin LC; Gale K; Kuhar MJ
Eur J Pharmacol; 1979 Dec; 60(2-3):229-35. PubMed ID: 43260
[TBL] [Abstract][Full Text] [Related]
16. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
[TBL] [Abstract][Full Text] [Related]
17. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
Gnanalingham KK; Milkowski NA; Smith LA; Hunter AJ; Jenner P; Marsden CD
Eur J Pharmacol; 1995 Apr; 277(2-3):235-41. PubMed ID: 7493614
[TBL] [Abstract][Full Text] [Related]
18. Use of [3H]spiperone for labelling dopaminergic and serotonergic receptors in bovine caudate nucleus.
Withy RM; Mayer RJ; Strange PG
J Neurochem; 1981 Nov; 37(5):1144-54. PubMed ID: 7299393
[TBL] [Abstract][Full Text] [Related]
19. Brain enkephalin receptors in Parkinson's disease.
Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptors in subcellular fractions from bovine caudate: enrichment of [3H]spiperone binding in a postsynaptic membrane fraction.
Near JA; Mahler HR
J Neurochem; 1981 Mar; 36(3):1142-51. PubMed ID: 7205263
[No Abstract] [Full Text] [Related]
[Next] [New Search]
